Zacks Research Comments on Corcept Therapeutics Incorporated’s Q1 2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Tuesday, October 1st. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.30 per share for the quarter, up from their prior estimate of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.33 EPS, Q3 2025 earnings at $0.39 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $1.50 EPS and FY2026 earnings at $2.15 EPS.

A number of other equities research analysts have also recently weighed in on CORT. Canaccord Genuity Group reaffirmed a “buy” rating and set a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Truist Financial upped their target price on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright upped their target price on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Finally, Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Corcept Therapeutics presently has an average rating of “Buy” and an average target price of $56.50.

Corcept Therapeutics Trading Down 1.8 %

CORT opened at $45.04 on Thursday. The business’s 50 day moving average is $37.10 and its 200-day moving average is $31.20. The stock has a market cap of $4.69 billion, a PE ratio of 42.49 and a beta of 0.45. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $47.71.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.09. The company had revenue of $163.80 million for the quarter, compared to analysts’ expectations of $155.14 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business’s revenue for the quarter was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 earnings per share.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently modified their holdings of CORT. GAMMA Investing LLC increased its stake in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 579 shares during the last quarter. Park Place Capital Corp acquired a new position in shares of Corcept Therapeutics in the second quarter worth $32,000. Atwood & Palmer Inc. acquired a new position in shares of Corcept Therapeutics in the second quarter worth $35,000. FinTrust Capital Advisors LLC boosted its holdings in Corcept Therapeutics by 318.7% in the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,348 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Corcept Therapeutics by 125.4% in the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,962 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now owns 22,772 shares of the company’s stock, valued at $1,053,888.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total transaction of $509,080.00. Following the sale, the insider now directly owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William Guyer sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the sale, the insider now directly owns 6,039 shares in the company, valued at $213,176.70. The disclosure for this sale can be found here. Insiders sold 34,251 shares of company stock worth $1,365,292 over the last ninety days. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.